Home
/
PTC THERAPEUTICS, INC.
/
Financials
/
Quarterly
PTC THERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PTC THERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$211.01M
Nov 4, 2025
Q2
2025
Jun 30, 2025
$178.88M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$1.18B
May 6, 2025
Q3
2025
Sep 30, 2024
$196.79M
Nov 4, 2025
Q2
2025
Jun 30, 2024
$186.70M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$210.12M
May 6, 2025
Q3
2024
Sep 30, 2023
$196.58M
Nov 7, 2024
Q2
2024
Jun 30, 2023
$213.81M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$220.38M
Apr 25, 2024
Q3
2023
Sep 30, 2022
$217.13M
Oct 26, 2023
Q2
2023
Jun 30, 2022
$165.53M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$148.74M
Apr 27, 2023
Q3
2022
Sep 30, 2021
$138.74M
Oct 27, 2022
Q2
2022
Jun 30, 2021
$116.68M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$117.94M
May 3, 2022
Q3
2021
Sep 30, 2020
$118.40M
Oct 28, 2021
Q2
2021
Jun 30, 2020
$75.24M
Jul 29, 2021
Q1
2021
Mar 31, 2020
$68.26M
May 4, 2021
Q3
2020
Sep 30, 2019
$71.42M
Oct 29, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$56.06M
May 9, 2018
Q3
2017
Sep 30, 2017
$41.85M
Nov 2, 2017
Q2
2017
Jun 30, 2017
$47.96M
Aug 9, 2017
Q1
2018
Mar 31, 2017
$26.55M
May 9, 2018
Q3
2017
Sep 30, 2016
$22.99M
Nov 2, 2017
Q2
2017
Jun 30, 2016
$15.63M
Aug 9, 2017
Q1
2017
Mar 31, 2016
$18.90M
May 8, 2017
Q3
2016
Sep 30, 2015
$9.78M
Nov 3, 2016
Q2
2016
Jun 30, 2015
$6.77M
Aug 4, 2016
Q1
2016
Mar 31, 2015
$7.48M
May 5, 2016
Q3
2015
Sep 30, 2014
$1.69M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$1.68M
Jul 31, 2015
Q1
2015
Mar 31, 2014
$9.22M
May 5, 2015
Q3
2014
Sep 30, 2013
$16.29M
Nov 6, 2014
Q2
2014
Jun 30, 2013
$6.85M
Aug 7, 2014
Q1
2014
Mar 31, 2013
$7.14M
May 6, 2014
Q3
2013
Sep 30, 2012
$7.20M
Nov 14, 2013
Q2
2013
Jun 30, 2012
$7.59M
Aug 13, 2013
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$15.90M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($64.85M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
$866.56M
May 6, 2025
Q3
2025
Sep 30, 2024
($106.65M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($99.18M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($91.58M)
May 6, 2025
Q3
2024
Sep 30, 2023
($132.97M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($198.88M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($138.96M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
($109.32M)
Oct 26, 2023
Q2
2023
Jun 30, 2022
($152.09M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($126.73M)
Apr 27, 2023
Q3
2022
Sep 30, 2021
($133.62M)
Oct 27, 2022
Q2
2022
Jun 30, 2021
($118.37M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($128.64M)
May 3, 2022
Q3
2021
Sep 30, 2020
($69.69M)
Oct 28, 2021
Q2
2021
Jun 30, 2020
($181.43M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($112.69M)
May 4, 2021
Q3
2020
Sep 30, 2019
($60.00M)
Oct 29, 2020
Q2
2020
Jun 30, 2019
($41.79M)
Aug 5, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$3.02M
Nov 4, 2025
Q2
2025
Jun 30, 2025
($34.96M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
$970.23M
May 6, 2025
Q3
2025
Sep 30, 2024
($54.51M)
Nov 4, 2025
Q2
2025
Jun 30, 2024
($40.22M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($45.45M)
May 6, 2025
Q3
2024
Sep 30, 2023
($118.16M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($209.54M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($117.62M)
Apr 25, 2024
Q3
2023
Sep 30, 2022
($68.19M)
Oct 26, 2023
Q2
2023
Jun 30, 2022
($92.36M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($86.52M)
Apr 27, 2023
Q3
2022
Sep 30, 2021
($93.08M)
Oct 27, 2022
Q2
2022
Jun 30, 2021
($98.49M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($98.15M)
May 3, 2022
Q3
2021
Sep 30, 2020
($55.13M)
Oct 28, 2021
Q2
2021
Jun 30, 2020
($187.27M)
Jul 29, 2021
Q1
2021
Mar 31, 2020
($92.99M)
May 4, 2021
Q3
2020
Sep 30, 2019
($60.48M)
Oct 29, 2020
Q2
2020
Jun 30, 2019
($38.76M)
Aug 5, 2020